Premarin vs. Bijuva
See how Premarin and Bijuva compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Premarin is an estrogen-only tablet approved for menopause symptoms, osteoporosis prevention, and certain hormone-sensitive cancers, while Bijuva is a combined estrogen-progesterone capsule approved only for hot flashes.
Women with a uterus need a separate progestin alongside Premarin, but Bijuva already includes bioidentical progesterone in every capsule.
Both drugs carry boxed warnings for blood clots, stroke, and dementia risk, so personal and family health history should factor into the choice between them.
Premarin vs. Bijuva Drug Summary
Premarin
Premarin is an estrogen hormone therapy made from conjugated estrogens, first approved by the FDA in 1942. It treats menopause symptoms like hot flashes and vaginal atrophy, low estrogen from ovarian failure, and is also used to prevent osteoporosis and palliate certain hormone-sensitive cancers. It is taken as a daily oral tablet, available in six strengths, or as a vaginal cream.
Bijuva
Bijuva is a combination hormone therapy containing bioidentical estradiol and progesterone in one daily capsule, approved by the FDA in 2018. It treats moderate to severe hot flashes caused by menopause in women who still have a uterus. It is taken once daily with food, since a high-fat meal boosts progesterone absorption.
Premarin vs. Bijuva Side Effects
Premarin
Bijuva
Premarin vs. Bijuva Dosage
Premarin
Bijuva
| STAGE | DOSE | WHEN |
| Starting dose | 0.3 mg once daily | At the start |
| Maximum dose | 10 mg three times daily | If needed |
| Dose changes | 5 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg once daily | At the start |
| Maximum dose | 1 mg/100 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Premarin
| STAGE | DOSE | WHEN |
| Starting dose | 0.3 mg once daily | At the start |
| Maximum dose | 10 mg three times daily | If needed |
| Dose changes | 5 increases | As tolerated |
Bijuva
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg once daily | At the start |
| Maximum dose | 1 mg/100 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Premarin vs. Bijuva Indications
Premarin
Premarin treats a range of menopause-related and hormone-deficiency conditions, from hot flashes to vaginal atrophy, and is also used to slow bone loss after menopause. It has additional FDA-approved uses outside menopause, including palliative treatment for certain hormone-sensitive cancers. Because it contains estrogen alone, it is often paired with a separate progestin in women who still have a uterus.
Moderate to severe hot flashes and night sweats
Vaginal dryness and irritation from menopause
Low estrogen from ovarian failure or removal
Prevention of osteoporosis after menopause
Bijuva
Bijuva is FDA-approved for one purpose: treating moderate to severe hot flashes caused by menopause. It combines estradiol and progesterone in a single capsule, which is why it is limited to women who still have a uterus and need the progesterone to protect the uterine lining. It does not carry the broader range of approvals that older estrogen products have accumulated over decades.
Moderate to severe hot flashes and night sweats
Only approved for women who still have a uterus
Provides both estrogen and progestin in one capsule
Not approved for vaginal atrophy or osteoporosis prevention
Premarin vs. Bijuva Pros and Cons
Premarin
Premarin has been on the market since 1942, giving it a long track record across many approved uses, including osteoporosis prevention and certain hormone-sensitive cancers. It carries the same class-wide boxed warnings for cancer, clot, and dementia risk as newer estrogen products.
Pros
Approved for a broader range of uses, including osteoporosis prevention and cancer palliation
Available in six dose strengths for precise titration
Long-standing FDA approval history dating back to 1942
Also available as a vaginal cream for localized symptoms
Cons
Requires a separate progestin prescription for women with a uterus
Made from conjugated equine estrogens rather than bioidentical hormones
Carries boxed warnings for endometrial cancer, stroke, and dementia risk
Bijuva
Bijuva is a newer, single-purpose option built around bioidentical hormones, which appeals to patients specifically seeking hot flash relief without a separate synthetic progestin. Its narrower approval means it is not an option for the additional uses Premarin covers, such as vaginal atrophy or osteoporosis prevention.
Pros
Combines bioidentical estradiol and progesterone in a single daily capsule
Progesterone already included, so no second prescription is needed
Uses hormones structurally identical to those the body produces
Simple two-strength dosing makes it easy to escalate if needed
Cons
Only approved for hot flashes, not vaginal atrophy or osteoporosis prevention
Not approved for women without a uterus
Must be taken with food, since a high-fat meal changes absorption
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.